Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on developing novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has announced its upcoming second quarter 2024 financial results release. The company will report its Q2 2024 financial and operating results before market open on Monday, August 12, 2024. Following the release, Y-mAbs will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Investors can access the call via domestic (877-407-0792) or international (201-689-8263) phone numbers, or through a live webcast link provided by the company.
Y-mAbs Therapeutics (Nasdaq: YMAB), una azienda biofarmaceutica in fase commerciale che si concentra sullo sviluppo di nuove radioimmunoterapie e prodotti terapeutici a base di anticorpi per il trattamento del cancro, ha annunciato l'imminente rilascio dei risultati finanziari del secondo trimestre 2024. La società comunicherà i risultati finanziari e operativi del Q2 2024 prima dell'apertura del mercato lunedì 12 agosto 2024. Dopo la diffusione dei risultati, Y-mAbs ospiterà una call e webcast alle 8:00 a.m. ET per discutere i risultati. Gli investitori possono accedere alla chiamata tramite numeri di telefono domestici (877-407-0792) o internazionali (201-689-8263), oppure tramite un link per il webcast fornito dall'azienda.
Y-mAbs Therapeutics (Nasdaq: YMAB), una compañía biofarmacéutica en etapa comercial enfocada en desarrollar novedosas radioinmunoterapias y productos terapéuticos basados en anticuerpos para el tratamiento del cáncer, ha anunciado la próxima divulgación de sus resultados financieros del segundo trimestre de 2024. La empresa informará sobre los resultados financieros y operativos del Q2 2024 antes de la apertura del mercado el lunes 12 de agosto de 2024. Tras la divulgación, Y-mAbs llevará a cabo una llamada y transmisión web a las 8:00 a.m. ET para discutir los resultados. Los inversores pueden acceder a la llamada a través de números de teléfono nacionales (877-407-0792) o internacionales (201-689-8263), o a través de un enlace de transmisión en vivo proporcionado por la compañía.
Y-mAbs Therapeutics (Nasdaq: YMAB)는 암 치료를 위한 새로운 방사면역요법과 항체 기반 치료 제품을 개발하는 데 집중하는 상업 단계의 생명공학 회사로, 곧 있을 2024년 2분기 재무 결과 발표를 발표했습니다. 회사는 2024년 8월 12일 월요일, 시장 개장 이전에 2024년 2분기 재무 및 운영 결과를 보고할 예정입니다. 발표 후 Y-mAbs는 오전 8시 ET에 실시간 전화 회의 및 웹캐스트를 개최하여 결과를 논의할 것입니다. 투자자들은 국내 전화번호(877-407-0792) 또는 국제전화번호(201-689-8263)를 통해, 또는 회사에서 제공하는 실시간 웹캐스트 링크를 통해 전화를 액세스할 수 있습니다.
Y-mAbs Therapeutics (Nasdaq: YMAB), une entreprise biopharmaceutique en phase commerciale axée sur le développement de nouvelles radioimmunothérapies et de produits thérapeutiques à base d'anticorps pour le traitement du cancer, a annoncé la prochaine publication de ses résultats financiers du deuxième trimestre 2024. La société publiera ses résultats financiers et opérationnels pour le Q2 2024 avant l'ouverture du marché le lundi 12 août 2024. Après la publication, Y-mAbs organisera une conférence téléphonique et un webinaire à 8h00 ET pour discuter des résultats. Les investisseurs peuvent accéder à l'appel via des numéros de téléphone nationaux (877-407-0792) ou internationaux (201-689-8263), ou via un lien de webdiffusion en direct fourni par la société.
Y-mAbs Therapeutics (Nasdaq: YMAB), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf die Entwicklung neuartiger Radioimmuntherapien und antikörperbasierter therapeutischer Produkte zur Krebsbehandlung konzentriert, hat die bevorstehenden Finanzergebnisse für das zweite Quartal 2024 angekündigt. Das Unternehmen wird seine Finanz- und Betriebsergebnisse für das Q2 2024 vor Markteröffnung am Montag, den 12. August 2024 bekanntgeben. Nach der Veröffentlichung wird Y-mAbs um 8:00 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen. Investoren können auf den Anruf über nationale (877-407-0792) oder internationale (201-689-8263) Telefonnummern zugreifen oder über einen von dem Unternehmen bereitgestellten Live-Webcast-Link.
- None.
- None.
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report second quarter 2024 financial and operating results before market open on Monday, August 12, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET.
Conference call and webcast details:
| Investors (domestic): | (877) 407-0792 |
| Investors (international): | (201) 689-8263 |
To access a live webcast of the update, please use this link.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond, including estimated operating expenses, cash burn and DANYELZA product revenue and sufficiency of cash resources and related assumptions; implied and express statements regarding the future of the Company’s business, including with respect to expansion and its goals; the Company’s plans and strategies, development, commercialization and product distribution plans; expectations with respect to the Company’s products and product candidates, including potential territory and label expansion of DANYELZA and the potential market opportunity related thereto and potential benefits thereof, and the potential of the SADA PRIT Technology and potential benefits and applications thereof; the Company’s mission of delivering better and safer therapies to patients; expectations relating to key anticipated development milestones, including potential expansion and advancement of commercialization and development efforts, including potential indications, applications and geographies, and the timing thereof; expectations with respect to current and future clinical and pre-clinical studies and the Company’s research and development programs, including with respect to timing and results; expectations related to the timing of the initiation and completion of regulatory submissions; additional product candidates and technologies; expectations regarding collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of cash and cash equivalents, and the need for, timing and amount of any future financing transaction; expectations with respect to the Company’s future financial performance; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,” “objective,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks associated with the Company’s development work; cost and success of the Company’s product development activities and clinical trials; the risks of delay in the timing of the Company’s regulatory submissions or failure to receive approval of its drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates; development of sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for products; the risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; the Company’s ability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s common stock, risks associated with macroeconomic conditions, including the conflict between Russia and Ukraine and sanctions related thereto, the state of war between Israel and Hamas and the related risk of a larger regional conflict, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems; and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney Dugan
VP, Head of Investor Relations
cdu@ymabs.com
FAQ
When will Y-mAbs Therapeutics (YMAB) release its Q2 2024 financial results?
What time is Y-mAbs Therapeutics (YMAB) Q2 2024 earnings call scheduled for?
How can investors access Y-mAbs Therapeutics (YMAB) Q2 2024 earnings call?
What is the main focus of Y-mAbs Therapeutics (YMAB)?
